Lantheus Holdings, Inc.

LNTH · Nasdaq · SIC 2835: In Vitro & In Vivo Diagnostic Substances
204
SEC Filings

Business Summary

Regulatory Matters to this Form 10-K. In connection with our ongoing development activities, we currently depend, and expect to continue to depend, on numerous third parties, including contract research organizations, clinical trial investigators and contract manufacturing organizations. If any of these service providers breach or terminate its agreement with us or otherwise fail to conduct the service for which it is responsible successfully and in a timely and compliant manner, the development...

Next Earnings

Q2 FY2026 — expected 2026-08-16

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLNTHdiscussed_in_filing Cybersecurity
topic_mentionLNTHdiscussed_in_filing Cybersecurity
topic_mentionLNTHdiscussed_in_filing Regulation
topic_mentionLNTHdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-073498EDGAR107K words
2025-02-262024-12-310001628280-25-007970EDGAR—
2024-02-222023-12-310001628280-24-006158EDGAR—
2023-02-232022-12-310001628280-23-004698EDGAR—
2022-02-242021-12-310001628280-22-003657EDGAR—
2021-02-252020-12-310001628280-21-003336EDGAR—
2020-02-252019-12-310001628280-20-002197EDGAR—
2019-02-202018-12-310001628280-19-001574EDGAR—
2018-02-262017-12-310001628280-18-002261EDGAR—
2017-02-232016-12-310001193125-17-053986EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-268113EDGAR45K words
2025-08-062025-06-300000950170-25-103544EDGAR—
2025-05-072025-03-310001628280-25-022872EDGAR—
2024-11-062024-09-300001628280-24-045459EDGAR—
2024-07-312024-06-300001628280-24-033630EDGAR—
2024-05-022024-03-310001628280-24-019798EDGAR—
2023-11-022023-09-300001628280-23-036214EDGAR—
2023-08-032023-06-300001628280-23-027015EDGAR—
2023-05-042023-03-310001628280-23-015464EDGAR—
2022-11-032022-09-300001628280-22-027986EDGAR—
2022-08-042022-06-300001628280-22-020872EDGAR—
2022-04-292022-03-310001628280-22-011291EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-260001193125-26-073439EDGAR6K words
2025-11-120001193125-25-277754EDGAR—
2025-11-060001193125-25-268103EDGAR—
2025-08-110001193125-25-178046EDGAR—
2025-08-060000950170-25-103543EDGAR—
2025-07-220001193125-25-162233EDGAR—
2025-05-070001628280-25-022871EDGAR—
2025-05-050001193125-25-112812EDGAR—
2025-04-010001193125-25-069927EDGAR—
2025-02-260001628280-25-007965EDGAR—

204 total filings indexed. 172 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

ACHV — ACHIEVE LIFE SCIENCES, INC. TKNO — Alpha Teknova, Inc. AWHL — Aspira Women's Health Inc. BMRA — BIOMERICA INC BZYR — BURZYNSKI RESEARCH INSTITUTE INC CDIO — Cardio Diagnostics Holdings, Inc. CLDX — Celldex Therapeutics, Inc. IDXX — IDEXX LABORATORIES INC /DE

Company Identity

CIK0001521036
TickerLNTH
ExchangeNasdaq
SIC2835: In Vitro & In Vivo Diagnostic Substances
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 606ff7fae0356bfcdf630525ec1a40ce1a8002d6a1e45b3d4197e36a3a98ec8c
parent: 94a65f0534054c4e1a1e584a533d786174f5721117fecb4216acd1932afb40d5
content hash: c0d413f4371086cb92bdde070790e7e9a7f2977bfe2227f785ca1d2bb2fbbfe1
signed: 2026-04-13T04:46:04.426Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf